Ceftriaxone sodium: adverse event reports filed with FDA

3,779

reports as suspect product

0% of all reports · about 170 a year

311

reports, 12 months to June 2026

344 in the 12 months before

93.3%

marked serious by the reporter

89.1% across the class

20.9%

record death among outcomes, as reported

789 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Ceftriaxone sodium reports recording the termmedian drug in cephalosporin antibacterial

1. Dyspnoeashortness of breath11.9%451
2. Drug hypersensitivityan allergic-type reaction to a medicine8.3%315
3. Drug ineffectivethe medicine did not work as expected8.3%312
4. Off label useused for a purpose or in a way not on the label7.9%300
5. Coughcough6.5%247
6. Urticariahives6.5%247
7. Vomitingbeing sick6.4%242
8. Nauseafeeling sick6.3%238
9. Asthmaasthma6.3%237
10. Multiple organ dysfunction syndromeseveral organs failing6.1%230
11. Abdominal painstomach or belly pain5.9%222
12. Chest discomfortchest discomfort5.5%209
13. Condition aggravatedthe condition being treated got worse5.5%209
14. Wheezingwheezing5.5%207
15. Breath sounds abnormal5.5%206
16. Full blood count abnormal5.4%205
17. Sepsisa severe body-wide response to infection5.3%200
18. Eosinophilia5.2%198
19. Abdominal distensiona bloated abdomen5.1%192
20. General physical health deteriorationgeneral decline in health5.1%192
21. Ascitesfluid in the abdomen4.9%186
22. Blood potassium decreased4.9%185
23. Chest X-ray abnormal4.9%184
24. Constipationconstipation4.8%182
25. Blood lactic acid increased4.8%181
26. Ear pruritus4.7%179
27. Appendicitis4.7%178
28. Rashskin rash4.7%178
29. Anaemialow red blood cells4.7%177
30. Appendicolith4.7%176

Top 30 of 763 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 17 drugs in the cephalosporin antibacterial class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 57,006 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 17.3% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 3,779 reports.

Drugs most often listed in the same reports

Other products listed in reports where Ceftriaxone sodium is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the cephalosporin antibacterial class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Ceftriaxone sodium as a suspect or interacting product; reports listing it only as a concomitant medication (2,111) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.